Market research
OXUR.BR Oxurion NV
BR EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 141K
- P/E ratio
- 0.01
- Analyst target
- 0.3
- Dividend yield
- Not available
- Beta
- 0.07
Profile
Instrument facts
- Exchange
- BR
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- BE0003846632
- Market cap
- 141K
- P/E ratio
- 0.01
- Analyst target
- 0.3
- Dividend yield
- Not available
- Beta
- 0.07
About
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. The company is developing ophthalmic treatments to preserve vision for patients geographic atrophy and wet age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Research context
Oxurion NV appears in PyInvesting’s Brussels Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the OXUR.BR discussion.
5 years, 6 months ago
Oxurion NV is currently in a long term downtrend where the price is trading 6.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 28.4.
Oxurion NV's total revenue sank by 41.1% to $1M since the same quarter in the previous year.
Its net income has increased by 29.0% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 9.3% to $-6M since the same quarter in the previous year.
Based on the above factors, Oxurion NV gets an overall score of 3/5.